Change to the Management Board of Carl Zeiss Meditec AG

  • Management Board member Jan Willem de Cler to leave the Company at his own request and on good terms.
  • The Supervisory Board has agreed to terminate his Management Board contract effective 30 September 2022.

Jena, Germany | 8 September 2022 | Carl Zeiss Meditec AG

Jan Willem de Cler, member of Carl Zeiss Meditec AG’s Management Board, has informed the Supervisory Board that he shall not be available for a further term of office. The Supervisory Board has acknowledged Jan Willem de Cler’s decision with regret and has today agreed to terminate his Management Board contract effective 30 September 2022. Jan Willem de Cler is leaving the Company on good terms.

“The Supervisory Board of Carl Zeiss Meditec AG would like to thank Jan Willem de Cler for his exceptionally high level of commitment and for the major successes he has achieved over his 18 years in a wide range of management roles at ZEISS. He was particularly instrumental in driving forward the ZEISS Medical Technology Segment and our culture,” said Dr. Karl Lamprecht, Chairman of the Supervisory Board of Carl Zeiss Meditec AG. “We wish him all the very best and every success in the future.”

The Company shall announce the future composition of the management team at a later date.

Press Contact

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors .meditec @zeiss .com

Jan Willem de Cler

Jan Willem de Cler (57) has been a member of the Management Board of Carl Zeiss Meditec AG since 2018. He joined ZEISS in 2004 as Managing Director of the Benelux sales company and subsequently also took over the management of the sales company in France and the medical device company France Chirurgie Instrumentation (FCI). In 2010, he was appointed Head of Surgical Ophthalmology at Carl Zeiss Meditec AG, later becoming a member of the Management Board responsible for HR, Global Operations and Service, among others. Prior to his career at ZEISS, he held a number of different positions at General Electric and GE Medical Systems, before co-founding and becoming Sales & Marketing Director of start-up company Global Healthcare Exchange Europe.

Brief Profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,531 employees worldwide, the Group generated revenue of €1,646.8m in fiscal year 2020/21 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For further information visit: www.zeiss.com/med

More information about Carl Zeiss Meditec AG Less information about Carl Zeiss Meditec AG
Press Contact

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors .meditec @zeiss .com

Share
Press Photos
Jan Willem de Cler
Further Articles

Carl Zeiss Meditec achieves double-digit growth in first half year of 2022/23 with declining earnings

Unfavorable product mix and increase in operating costs impact EBIT margin

Carl Zeiss Meditec generated revenue of around €974.5m in the first six months of fiscal year 2022/23 (prior year: €8...

9 May 2023

ZEISS Presents New Surgical Workflow Innovations at ASCRS

New products help doctors diagnose and treat patients within the cataract and corneal refractive workflows.

ZEISS Medical Technology will showcase new surgical workflow innovations at the ASCRS 2023. As part of the ZEISS Medi...

2 May 2023

ZEISS Announces U.S. FDA Approval of the CT LUCIA 621P Monofocal IOL, Offering the Unique ZEISS Optic to the U.S. Market

The monofocal IOL enables surgeons to treat a wide range of cataract patients while supporting optimized visual outco...

25 Apr 2023